| HOME >> BIOLOGY >> TECHNOLOGY |
Dr. Lawrence A. Rheins Joins Histogen Aesthetics as President
San Diego/Phoenix (PRWEB) October 20, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn dermal fibroblasts, today announced the creation of Histogen Aesthetics LLC, a venture developing products for the growing medical aesthetic industries based on Histogen's core technology.
From a proprietary bioreactor process in which newborn fibroblasts are grown under proprietary embryonic-like conditions, Histogen Aesthetics extracts a unique complex - ReGenicaTM - made up of the naturally secreted growth factors, antioxidants and other synergistic bio-products that are produced. This complex will become the active ingredient in the Histogen Aesthetics line of products for skin, hair and nail care.
A recent clinical study of 49 patients, in which ReGenica was used as a treatment following an ablative cosmetic laser procedure, revealed improvement of overall skin condition in comparison to the vehicle control. Histogen Aesthetics is beginning follow-up studies of ReGenica for post-laser resurfacing, as well as topical skin and hair anti-aging applications.
Dermatology, cosmetics and biotechnology industry veteran Lawrence A. Rheins, Ph.D. has joined Histogen Aesthetics, LLC as President.
"The market for next generation, novel cosmeceuticals is rapidly evolving, including the movement of physician-dispensed, non-prescription products beyond the traditional medical specialties of plastic surgery and cosmetic dermatology, and into other medical specialties," said Rheins. "There is a continuing need for adjunct palliative skin conditioning products for use following all sorts of minimally and more invasive cosmetic procedures - laser, dermabrasion - by physicians engaged in aesthetic medicine."
Based on Histogen Aesthetics' ini
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |